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Abstract  
In-vitro studies of autosomal dominant Alzheimer’s disease implicate longer amyloid-beta 
peptides in disease pathogenesis, however less is known about the behaviour of these mutations 
in-vivo. In this cross-sectional cohort study, we used liquid chromatography-tandem mass 
spectrometry to analyse 66 plasma samples from individuals who were at-risk of inheriting a 
mutation or were symptomatic. We tested for differences in amyloid-beta42:38, 42:40 and 
38:40 ratios between presenilin1 and amyloid precursor protein carriers. We examined the 
relationship between plasma and in-vitro models of amyloid-beta processing and tested for 
associations with parental age at onset. 39 participants were mutation carriers (28 presenilin1 
and 11 amyloid precursor protein). Age- and sex-adjusted models showed marked differences 
in plasma amyloid-beta between genotypes: higher amyloid-beta42:38 in presenilin1 versus 
amyloid precursor protein (p<0.001) and non-carriers (p<0.001); higher amyloid-beta38:40 in 
amyloid precursor protein versus presenilin1 (p<0.001) and non-carriers (p<0.001); while 
amyloid-beta42:40 was higher in both mutation groups compared to non-carriers (both 
p<0.001). Amyloid-beta profiles were reasonably consistent in plasma and cell lines. Within 
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presenilin1, models demonstrated associations between amyloid-beta42:38, 42:40 and 38:40 
ratios and parental age at onset. In-vivo differences in amyloid-beta processing between 
presenilin1 and amyloid precursor protein carriers provide insights into disease 
pathophysiology, which can inform therapy development. 
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Introduction  
Understanding Alzheimer’s disease pathogenesis is critical to realising disease-modifying 
treatments. Autosomal dominant Alzheimer’s disease (ADAD), caused by mutations in 
presenilin 1/2 (PSEN1/2) or amyloid precursor protein (APP), is a valuable model for 
characterising the molecular drivers of Alzheimer’s disease.1 
 
PSEN1, the catalytic subunit of γ-secretase, sequentially cuts APP: initial endopeptidase 
cleavage generates an amyloid-beta (Aβ) peptide, either Aβ49 (major product) or Aβ48 (minor 
product).2 Subsequent proteolysis largely occurs down two pathways: Aβ49>46>43>40 or 
Aβ48>45>42>38.3 As Aβ49 is the predominant endopeptidase cleavage product, normal APP 
processing largely leads to Aβ40 formation.2 Pathogenic ADAD mutations alter APP 
processing resulting in more, and/or longer, aggregation prone, Aβ peptides, which accelerate 




Both APP and PSEN1/2 mutations increase production of longer (e.g. Aβ42) relative to shorter 
(e.g. Aβ40) peptides.5 However, there are intriguing inter-mutation differences in Aβ profiles. 
PSEN1 mutant lines produce increased Aβ42:38 ratios reflecting impaired γ-secretase 
processivity.5,6 In contrast, APP mutations at the γ-secretase cleavage site increase Aβ38:40 
ratios, consistent with preferential processing down the Aβ48 pathway.6 To date, studies 
examining the influence of ADAD genotypes on Aβ ratios in-vivo have been lacking.  
 
Increasingly sensitive mass spectrometry-based assays now make it possible to measure 
concentrations of different Aβ moieties in plasma.7 Therefore, we aimed to analyse plasma Aβ 
levels in an ADAD cohort, explore influences of genotype and clinical stage, and examine 
relationships between ratios and both parental age at onset (AAO) and estimated years to/from 
symptom onset (EYO), while also assessing consistency with in-vitro models of Aβ processing. 
Materials and methods  
Study design and participants 
We recruited 66 participants from UCL’s longitudinal ADAD study; details described 
previously.1 Samples were collected from August 2012 to July 2019 and concomitantly a semi-
structured health questionnaire and clinical dementia rating (CDR) scale were completed.8 
EYO was calculated by subtracting parental AAO from the participant’s age. Participants were 
defined as symptomatic if global CDR was >0. ADAD mutation status, determined using 
Sanger sequencing, was provided only to statisticians, ensuring blinding of participants and 
clinicians. The study had local Research Ethics Committee approval; written informed consent 
was obtained from all participants or a consultee. 
Measurement of plasma Aβ levels 
EDTA plasma samples were processed, aliquoted, and frozen at −80°C according to 
standardised procedures and shipped frozen to the Clinical Neurochemistry Laboratory, 
Sahlgrenska University Hospital, for analysis blinded to participants’ mutation status and 
diagnosis. Samples were analysed using a liquid chromatography-tandem mass spectrometry 
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method using an optimized protocol for immunoprecipitation for improved analytical 
sensitivity (Appendix 1, Supplementary Fig. 1, Supplementary Fig 2).9 Pooled plasma samples 
were used to track assay performance; intra- and inter-assay coefficients of variation were <5%. 
Correlation of Aβ ratios in plasma and in induced pluripotent stem 
cell (iPSC) neurons  
A sub-study investigated the consistency of Aβ profiles between plasma and iPSC-derived 
neurons. Aβ profiles were compared based on mutation for 8 iPSC-lines; data from 6 iPSC-
lines previously reported by Arber et al.6. Mutations tested were APP V717I (n=2), PSEN1 
Intron 4 (n=1), Y115H (n=1), M139V (n=1), R278I (n=1) and E280G (n=2). Plasma and iPSC 
samples were from the same participant or, where matched plasma was unavailable, plasma 
from a carrier of the same mutation, and if possible a family member. Aβ42:40, Aβ38:40 and 
Aβ42:38 ratios were normalised by taking the ratio of the value for each mutation carrier to the 
control median for each experimental setting (n=27 non-carriers for plasma, n=5 iPSC controls 
lines from non-ADAD families) (ratio values Supplementary Table 1).  
 
iPSC-neuronal Aβ was quantified as previously reported Arber et al.6. Briefly, iPSCs were 
differentiated to cortical neurons for 100 days and then 48 hour-conditioned culture supernatant 
was centrifuged removing cell debris. Aβ was analysed via electrochemiluminescence on the 
MSD V-Plex Aβ peptide panel (6E10), according to manufacturer’s instructions.  
Statistical analysis  
Summary descriptive statistics were calculated by mutation type (PSEN1, APP, non-carriers) 
and box plots produced for Aβ42:38, Aβ38:40 and Aβ42:40 ratios. Box plots were presented 
by mutation type (PSEN1 vs APP vs non-carriers), and then individually for PSEN1 and APP 
carriers by clinical stage (presymptomatic vs symptomatic vs non-carriers) (Fig. 1). Aβ ratios 
are displayed on logarithmic scales. Age- and sex-adjusted differences were estimated between 
mutation type for each ratio; as were differences by clinical stage for each ratio, separately for 
APP and PSEN1 carriers. These comparisons were made using mixed models including random 
intercepts for clusters comprising individuals from the same family and group, with random 
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intercept and residual variances allowed to differ for the groups being compared. Pairwise 
comparisons were only carried out if a joint test provided evidence of differences. Ratios were 
log-transformed; estimated coefficients were back-transformed to multiplicative effects.  
 
The relationship between parental AAO, EYO and age (EYO = age – AAO) means that it is 
not possible to estimate separate effects of AAO and EYO on Aβ ratios adjusting for age using 
a conventional statistical analysis: if age is held constant then a one-year increase in AAO 
implies a one year decrease in EYO and vice versa, hence their effects are aliased. However 
the aim here should be to allow for ‘normal ageing’ (as observed in non-carriers), and this is 
possible. For each combination of mutation carrier group (PSEN1 and APP) and Aβ ratio a 
separate mixed model was fitted jointly to the carrier group and the non-carrier group. Each 
model allowed the logarithm of the Aβ ratio to depend on AAO, EYO and sex (but not age) in 
the carrier group, and on just sex and age (estimating ‘normal ageing’) in the non-carrier group. 
Random effects were included as in the between group comparisons above. In the carrier group 
the effect of AAO adjusted for EYO, sex and (non-carrier) ‘normal ageing’ was obtained by 
subtracting the ‘normal ageing’ effect from the AAO effect (adjusted for sex and EYO). 
Analogously the effect of EYO adjusted for AAO, sex and ‘normal ageing’ was obtained by 
subtracting the ‘normal ageing’ effect from the EYO effect (adjusted for sex and AAO) in the 
carrier group. For Aβ42:38 in PSEN1 carriers there was evidence also to include a quadratic 
term for parental AAO. For each analysis the estimated geometric mean ratio (and 95% 
confidence interval) was plotted against parental AAO, standardising to an equal mix of 
males/females, an EYO of 0 (i.e. the point of symptom onset), and adjusted for ‘normal ageing’ 
relative to age 43 (the average age of mutation carriers). Analogous plots of estimated 
geometric mean ratio (and 95% confidence interval) against EYO were standardised to an equal 
mix of males/females, an AAO of 43 (average age of mutation carriers), and adjusted for 
‘normal ageing’ relative to age 43.  
 
Spearman correlation coefficients were calculated to assess the association between plasma 
and iPSC-neuron Aβ ratios. 
 




Data are available upon reasonable request from qualified investigators, adhering to ethical 
guidelines. 
Results  
Demographic and clinical characteristics are presented in Table 1: 27 non-carriers; 39 mutation 
carriers (28 PSEN1, 11 APP); Supplementary Table 2 gives mutation details.  
 
Age- and sex-adjusted models showed marked differences in plasma Aβ between PSEN1 and 
APP carriers. The geometric mean of Aβ42:38 was higher in PSEN1 compared to both APP 
carriers (69% higher, 95%CI: 39%, 106%; p<0.001) and non-carriers (64% higher, 95%CI: 
36%, 98%; p<0.001), while there was no evidence of a difference between APP carriers and 
non-carriers (p= 0.60) (Fig. 1A). 
 
Plasma Aβ42:40 was raised in both PSEN1 and APP; compared to non-carriers the adjusted 
geometric mean was 31% higher (95%CI: 16%, 49%; p<0.001) in PSEN1 and 61% higher 
(95%CI: 44%, 80%; p<0.001) in APP (Fig. 1D). There were also inter-mutation differences in 
Aβ42:40: the geometric mean was 22% higher (95%CI: 8%, 38%; p=0.001) in APP compared 
to PSEN1 carriers.  
 
The geometric mean of Aβ38:40 was higher in APP carriers compared to both PSEN1 carriers 
(101% higher, 95%CI: 72%, 135 %; p<0.001) and non-carriers (61% higher, 95%CI: 41%, 
84%; p<0.001) (Fig. 1G). While in PSEN1, Aβ38:40 was reduced compared to non-carriers 
(geometric mean 20% lower, 95%CI: 10%, 29%, p<0.001).  
 
For Aβ42:40 ratios, group differences remained significant when separately comparing non-
carriers to (i) presymptomatic (18% higher, 95%CI: 3%, 36%, p=0.02) and symptomatic (47% 
higher, 95% CI: 23%, 76%, p<0.001) PSEN1 carriers, and to (ii) presymptomatic (62% higher, 
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95% CI: 44%, 82%, p<0.001) and symptomatic (62% higher, 95% CI: 37%, 92%, p<0.001) 
APP carriers (Figs. 1E, 1F). Within PSEN1, the geometric mean of Aβ42:40 was also 24% 
higher (95%CI: 2%, 52%; p=0.03) in symptomatic compared to presymptomatic carriers (Fig. 
1E). There were no statistically significant differences between presymptomatic and 
symptomatic PSEN1 carriers in Aβ42:38 (p=0.11; Fig 1B) or Aβ38:40 (p=0.54; Fig. 1H). 
Additionally, no significant differences were observed in the Aβ42:40, Aβ42:38 or Aβ38:40 
ratios between presymptomatic and symptomatic APP carriers (all p-values>0.50) (Fig. 1C, 
1F, 1I).  
 
Using models that adjusted for sex, EYO and ‘normal ageing’, we found significant 
associations between all three ratios and parental AAO in PSEN1 carriers (all p-values <0.03) 
(Fig. 2). Higher Aβ42:38 and Aβ42:40 ratios were associated with earlier parental onset, while 
higher Aβ38:40 was associated with a later disease onset. For Aβ42:38 we included a quadratic 
term (p=0.003), which resulted in the estimated rate of change of Aβ42:38 reducing as parental 
AAO increased; a one-year increase in parental AAO was associated with a 9.4% decrease 
(95% CI: 5.3%,13.3%; p<0.001) in the geometric mean of Aβ42:38 at age 35 compared to a 
4.4% decrease (95% CI: 2.9%, 5.9%; p<0.001) in the same measure at age 45. For both 
Aβ42:40 and Aβ38:40, the association with parental AAO was estimated to be constant across 
the age range investigated, a one-year increase in parental AAO was associated with a 1.6% 
decrease (95% CI: 0.2%, 3.1%; p=0.03) in Aβ42:40 and a 1.7% increase (95% CI: 0.4%, 3.0%; 
p=0.008) in the Aβ38:40. In APP carriers, there were no significant associations between 
Aβ42:40, Aβ42:38 or Aβ38:40 and parental AAO (all p-values ≥0.18; Supplementary Fig. 3).  
 
In PSEN1 and APP carriers, models that adjusted for sex, parental AAO and ‘normal ageing’ 
did not find any significant association between either Aβ42:40, Aβ42:38 or Aβ38:40 and EYO 
(Supplementary Figs. 4,5) (p≥0.06). However, in APP carriers there was weak evidence of an 
association between Aβ42:40 and EYO: a one-year increase in EYO was associated with a 





Aβ ratios in plasma and iPSC-conditioned media were highly associated for both Aβ42:40 
(rho=0.86, p=0.01) and Aβ38:40 (rho=0.79, p=.02), somewhat less so for Aβ42:38 (rho=0.61, 
p=0.10) (Fig. 3). While we did not observe perfect agreement in the Aβ42:38 ratio between 
plasma and iPSC lines (shown by solid line, Fig. 3), the direction of change in this ratio, i.e. 
either increased or decreased when compared to controls, was largely consistent across media. 
Discussion  
In this study we found increases in plasma Aβ42:40 in both APP and PSEN1 carriers compared 
to non-carriers and marked differences in Aβ ratios between genotypes: Aβ42:38 was higher 
in PSEN1 vs. APP, Aβ38:40 was higher in APP vs. PSEN1. Importantly, more aggressive 
PSEN1 mutations (those with earlier ages of onset) had higher Aβ42:40 and Aβ42:38 ratios – 
in-vivo evidence of the pathogenicity of these peptide ratios.  
 
These results offer insights into the pathobiology of ADAD and differential effects of 
APP/PSEN1 genotype. Increased Aβ42:38 in PSEN1 may be attributed to reduced conversion 
of Aβ42 (substrate) to 38 (product) relative to non-carriers – in contrast APP carriers showed 
near identical Aβ42:38 ratios compared to non-carriers. Strikingly, increases in Aβ42 relative 
to shorter Aβ moieties (≤40) were associated with earlier disease onset in PSEN1. Importantly 
there were no associations between Aβ ratios and EYO in PSEN1 carriers, suggesting these 
ratios represent molecular drivers of disease as opposed to being markers of disease stage. Our 
in-vivo results recapitulate cell-based findings of reduced efficiency of γ-secretase processivity 
in PSEN1 6,10,11; inefficiency attributed to impaired enzyme-substrate stability causing 
premature release of longer Aβ peptides.10 
 
Parental AAO is an indicator of disease severity, with a younger AAO implying a more 
deleterious mutation. In PSEN1 Ab42:38 (a read-out of the efficiency of the fourth γ-secretase 
cleavage) showed a deceleration in the rate of change as parental AAO increases. This further 
supports the central pathogenic role of γ-secretase processivity in ADAD, especially in younger 




In APP, production of Ab38 relative to Ab40 was increased. This is consistent with a shift in 
the site of endopeptidase-cleavage causing increased generation of Aβ48; the precursor 
substrate in the Aβ38 production line. Our study included APP mutations located near the γ-
secretase cleavage site. Previous cell-based work involving mutations around this site also 
demonstrated increased trafficking along the Ab48 pathway.5,6,11 In contrast, APP duplications 
or mutations near the beta-secretase site are associated with non-differential increases in Aβ 
production.12  
 
Changes in Aβ38:40 were also seen in PSEN1 carriers; levels were reduced compared to both 
APP carriers and non-carriers. Declines in Aβ38:40 may reflect mutation effects on 
endopeptidase cleavage and/or γ-secretase processivity; changes in both processes have been 
described in in-vitro studies of PSEN1.6,13 Premature release of longer (>Aβ43) peptides may 
contribute to falls in Aβ38:40; both increasing Aβ length and pathogenic PSEN1 mutations are 
associated with destabilisation of the enzyme-substrate complex.10 It will be important for 
future research to investigate the exact molecular drivers of declines in Aβ38:40 in PSEN1, 
especially as lower levels were associated with earlier disease onset.  
 
We also saw inter-stage differences in APP processing; Aβ42:40 was higher in symptomatic 
compared to presymptomatic PSEN1 carriers. The reason for this is unclear and should be 
treated cautiously given small group sizes and the absence of inter-stage differences in Aβ42:40 
amongst APP carriers. However, post-symptomatic increases in plasma Ab42 have been 
reported in Down syndrome.14 It is possible that downstream pathogenic consequences of 
ADAD, such as cerebral amyloid angiopathy, may interact with, and modify, plasma levels. 
Additionally, as Aβ is produced peripherally in organs, muscle and platelets, systemic factors 
may contribute to inter-stage differences.15  
 
Our results support the hypothesis that ADAD mutations increase in-vivo production of longer 
Aβ peptides (Aβ≥42) relative to Aβ40. This is consistent with cell- and blood-based studies in 
ADAD.11,16 Additionally, we showed plasma Aβ profiles were recapitulated in iPSC-media 
with consistent profiles for the same mutation. There is some evidence that Aβ42:40 ratios also 
increase in the CSF of mutation carriers far from onset, however CSF levels then fall 
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significantly during the two decades before symptom onset17; reductions are attributed to 
“trapping” of longer peptides within cerebral plaques.18 In sporadic Alzheimer’s disease CSF, 
as well as plasma, Aβ42:40 levels also fall as cerebral amyloid plaques start to accumulate, 
with ratio levels remaining low thereafter.19 In contrast, we show that plasma Aβ42:40 in both 
APP and PSEN1 carriers was raised and did not fall below non-carriers levels, either before or 
after symptom onset. Taken together, these findings suggest that plasma Aβ ratios in ADAD 
are less susceptible to the effects of sequestration.  
 
 Study limitations include the small sample size, due to the rarity of ADAD, however we 
included a reasonably wide array of mutations. Secondly, ages at onset were estimated from 
parental AAO, while this offers a reasonable estimate there is variability within families and 
imprecision in determining AAO in a preceding, often deceased, generation.20 Finally, future 
studies should measure Aβ moieties longer than Aβ42, and also investigate interactions 
between central and peripheral Aβ production (we lacked paired CSF).  
 
In conclusion, we demonstrate the impact of pathogenic ADAD mutation on APP processing 
in-vivo. We show marked inter-mutation difference in Aβ profiles, with relative increases in 
longer peptides being associated with earlier disease onset. Our findings suggest that plasma 
Aβ ratios in ADAD may be useful biomarkers of APP processing. This is especially important 
as we enter an era of gene silencing therapies, and personalised medicine, where direct read-
outs of gene function will be particularly valuable. 
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Figure 1: Box plots for observed plasma Aβ ratios. Plasma (1A-C) Aβ42:38, (1D-F) 
Aβ42:40 and (1G-I) Aβ38:40 ratios are shown with the y-axis on a logarithmic scale. Mutation 
carriers were divided into (1A, 1D, 1G) APP and PSEN1 carriers and non-carriers; (1B, 1E, 
1H) PSEN1 presymptomatic and symptomatic mutation carriers and non-carriers and (1C, 1F, 
16 
 
1I) APP presymptomatic and symptomatic mutation carriers and non-carriers. Boxes show the 
median and first and third quartiles. Dots represent individual observations.  
 
Figure 2: Plasma Aβ ratios against parental AAO in PSEN1 carriers.  
Scatter plots of observed plasma (A) Aβ42:38 (C) Aβ42:40 and (E) Aβ38:40 values against 
parental age at onset (AAO). Symptomatic mutation carriers are identified by square symbols 
and presymptomatic mutation carriers by triangle symbols. 
Modelled geometric mean of plasma (B) Aβ42:38 (D) Aβ42:40 and (F) Aβ38:40 against 
parental AAO in PSEN1 carriers; models adjust for EYO, sex and ‘normal ageing’ in non-
carriers. The trajectories displayed contain an equal mix of males/females and are adjusted for 
‘normal ageing’ relative to age 43 (the average age of mutation carriers). EYO is set at 0, i.e. 
point of symptom onset, in all three trajectory plots.  




Figure 3: Comparison of Aβ processing in-vivo and in-vitro. Scatterplot comparing Aβ ratios 
profiles in plasma and iPSC derived neurons for eight mutation carriers. One to one comparison 
of Aβ ratios normalised to the median of controls for each experimental setting (n=27 non-
carrier controls for plasma, n=5 iPSC lines from controls who were not members of ADAD 
families); values >1 indicate higher ratio in mutation carrier compared to median of controls 
whereas values <1 indicate lower ratio in mutation carrier compared to median of controls. 
Matched samples (plasma and iPSC samples donated by the same donor) are identified with 
triangle symbols. Unmatched samples (plasma and iPSC samples donated by different 
participants who carry the same mutation, and where possible are members of the same family) 
are identified by square symbols. The y-axis scale is logarithmic in all panes. Spearman’s rho 
and the associated p-value are shown for each scatter plot. The line displayed on each 
18 
 
scatterplot represents line of perfect agreement i.e. x=y. 
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Controls SEN1 carriers APP carriers
Figure 1: Representative mass spectrometry (MS) spectra for Aβ38, Aβ40 and Aβ42.
Representative MS profiles for 3 non-carrier controls (1A, 1D, 1G), 3 PSEN1 carriers (1B, 1E, 1H) and APP carriers (1C, 1F, 1I). Panes 1B and 1C display profiles of presymptomatic mutation carriers, while panes 1E, 1F,1H, 1I display 
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Supplementary figure 2: Representative chromatograms of the detected peptides and their corresponding internal standards 
Representative chromatograms for 3 non-carrier controls (1A, 1D, 1G), 3 PSEN1 carriers (1B, 1E, 1H) and APP carriers (1C, 1F, 1I). Panes 1B and 1C display profiles of 











Supplementary figure 5: Plasma Aβ ratios against estimated years to/from symptom onset 
(EYO) in APP carriers. 
Scatter plots of observed plasma (A) Aβ42:38 (C) Aβ42:40 and (E) Aβ38:40 values against EYO. 
All scatter plots show values for APP carriers only. Symptomatic mutation carriers are identified 
by square symbols and presymptomatic mutation carriers by triangle symbols.
Modelled geometric mean of plasma (B) Aβ42:38 (D) Aβ42:40 and (F) Aβ38:40 against EYO in 
APP carriers. The trajectories displayed contain an equal mix of males/females and are adjusted 
to ‘normal ageing’ in non-carriers relative to age 43 (average age of mutation carriers). Parental 
AAO is set at 43 in all three trajectory plots. Models, which adjusted for parental AAO, sex and 
‘normal ageing’, did not show evidence of any significant associations between either Aβ42:38,
Aβ42:40 or Aβ38:40 and EYO: for Aβ42:38 a one-year increase in EYO was associated with an 
estimated 0.2% decrease (95% CI: 1.2% decrease, 0.7% increase; p=0.63); for Aβ42:40 an 
estimated 0.8% decrease (95% CI: 1.6% decrease, 0.0% increase; p=0.06); for Aβ38:40 an 
estimated 0.6% decrease  (95% CI:1.5% decrease, 0.3% increase; p=0.21). To maintain blinding 
of mutation status, the values of the x-axis for all EYO plots have been removed. The y-axis scale 























































































































Gene Mutation Number of individuals 
APP 
p.Thr719Asn 1 AR 
p.Val717Gly 2 S 
p.Val717Ile 1 S, 7 AR  
p.Val717Leu 2 S, 2 AR 
PS1 
Intron 4 2 S, 5 AR 
p.Ala79Val 1 S 
p.Tyr115His 1 S, 1 AR 
p.Glu120Lys 1 AR 
p.Ser132Ala 2 AR 
p.Met139Val 1 S, 1 AR 
p.Val142Ile 1 S 
p.Met146Ile 2 AR 
p.Glu184Asp 2 S, 4 AR 
p.Ile202Phe 4 AR 
p.Gly206Ala 1 S 
p.His214Tyr 3 AR 
p.Ala246Glu 2 AR 
p.Pro264Leu 2 AR 
p.Pro267Ser 1 S 
p.Arg269His 1 AR 
p.Arg278Ile 3 AR, 
p.Glu280Gly 2 S, 6 AR,  
ΔE9* 1 S 
